Reaction
Angular Cheilitis reporting signals
As of the last recalculation, Angular Cheilitis appears in 676 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is REGORAFENIB (PRR 32.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Regorafenib | 12 | 32.4 | 32.4 |
| Panitumumab | 13 | 26.0 | 26.1 |
| Cladribine | 8 | 25.9 | 25.9 |
| Indapamide | 14 | 24.5 | 24.6 |
| Pyrazinamide | 4 | 13.2 | 13.2 |
| Bimekizumab | 9 | 13.2 | 13.2 |
| Trametinib | 10 | 12.9 | 12.9 |
| Peginterferon Alfa-2A | 18 | 10.5 | 10.5 |
| Cabozantinib | 16 | 10.5 | 10.5 |
| Irinotecan Hydrochloride | 4 | 9.6 | 9.6 |
| Isotretinoin | 15 | 9.5 | 9.5 |
| Ixekizumab | 8 | 6.7 | 6.7 |